Login to Your Account

Earnings Roundup

Friday, January 6, 2012

• InterMune Inc., of Brisbane, Calif., reported preliminary fourth-quarter net sales of idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) totaling about $2.8 million. The drug, which gained approval in Europe last year, has been launched in Germany, with about 612 patients prescribed since mid-September. InterMune plans to launch Esbriet in France, Spain and Italy in the second quarter and in the UK in October.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription